Neratinib
2020-0198
Phase 2 small_molecule terminated
Quick answer
Neratinib for Metastatic Breast Cancer is a Phase 2 program (small_molecule) at PUMA BIOTECHNOLOGY, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- PUMA BIOTECHNOLOGY, INC.
- Indication
- Metastatic Breast Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated